Cogent Biosciences is a biotechnology company dedicated to developing solutions for genetically driven diseases. The company employs rational drug discovery and development approaches to create precision therapies that target the underlying causes of these conditions. Cogent’s lead candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to address the KIT D816V mutation, linked to systemic mastocytosis and gastrointestinal stromal tumors. Currently, Cogent is conducting clinical trials to investigate the efficacy of bezuclastinib for these indications. With a commitment to advancing treatments that offer real hope to patients, Cogent Biosciences emphasizes collaboration, scientific rigor, and a patient-centric focus in its mission to improve healthcare outcomes for those suffering from rare diseases.